News BioInvent International AB

Equities

BINV

SE0015244520

Real-time Estimate Cboe Europe Other stock markets 01:07:28 30/04/2024 pm IST			5-day change	1st Jan Change
26.02 ^SEK	+2.87%		+11.97%	+38.19%

24/04	BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStock: BioInvent selected to present at ASCO in Chicago	29/04	AQ
BioInvent International AB, Interim report January-March 2024	25/04	AQ
BioInvent Q1 2024 - Approaching Catalysts	25/04	AQ
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024	24/04	AQ
BioInvent International AB: Interim report January-March 2024	24/04	AQ
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04	CI
BioInvent International AB publishes Annual Report 2023	04/04	AQ
BioStock: BioInvent deepens collaboration with MSD	04/04	AQ
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	03/04	AQ
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	03/04	MT
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04	PU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04	AQ
Notice to Annual General Meeting in BioInvent International AB	27/03	AQ
BioStock: BioInvent's CEO comments on the study success in China	11/03	AQ
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	06/03	AQ
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	05/03	PU
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	05/03	AQ
BioInvent International AB Year-end report January 1, December 31, 2023	23/02	AQ
BioInvent Q4 2023 - Now a mid-stage clinical company	23/02	AQ
Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024	22/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioInvent International AB

Equities

BINV

SE0015244520

Summary

Filters